Refine
Has Fulltext
- yes (13)
Is part of the Bibliography
- yes (13)
Year of publication
- 2015 (13) (remove)
Document Type
- Journal article (13) (remove)
Language
- English (13) (remove)
Keywords
- positron emission tomography (4)
- CXCR4 (2)
- bone disease (2)
- cancer (2)
- chemokine receptor (2)
- glioblastoma multiforme (2)
- in vivo imaging (2)
- involvement (2)
- lymphoma (2)
- management (2)
- multiple myeloma (2)
- radioiodine therapy (2)
- radiotherapy (2)
- survival (2)
- 1st International Workshop (1)
- 53BP1 (1)
- B-cell lymphoma (1)
- BRAF(V600E) mutation (1)
- C-11-methionine pet (1)
- CXCR4/SDF-1 (1)
- FDG (1)
- FDG PET/CT (1)
- FDG-PET/CT (1)
- FDG-PET/MRI (1)
- Hodgkin-lymphoma (1)
- P-glycoprotein expression (1)
- PET (1)
- SPECT (1)
- Simvastatin (1)
- Technetium Tc 99m Sestamibi Rats (1)
- WB-DW-MRI (1)
- \(^{11}\)C-Methionine-PET (1)
- \(^{18}\)F-FDG PET/CT (1)
- acute myeloid leukemia (1)
- adrenocortical (1)
- analysis (1)
- areas (1)
- association (1)
- autologous transplantation (1)
- brain tumors (1)
- calcitonin (1)
- carcinoma (1)
- carcinoma metastases to pancreas (1)
- cardiac neurohormonal system (1)
- cells (1)
- cerebral gliomas (1)
- children (1)
- chromatin mobility (1)
- coefficient (1)
- damage (1)
- delineation (1)
- diffusion weighted MRI (1)
- dissection (1)
- distant metastases (1)
- dose response (1)
- esophagogastric junction (1)
- experience (1)
- exposure (1)
- follow-up (1)
- glioma (1)
- guidelines (1)
- heart (1)
- heart failure (1)
- histone H2AX (1)
- imaging techniques (1)
- immunostaining (1)
- improves (1)
- in vivo formation (1)
- inflammation (1)
- initial experience (1)
- iodine nutrition (1)
- kinase inhibitor (1)
- macrophages (1)
- magnetic resonance imaging (1)
- malignancies (1)
- malignant lymphoma (1)
- mechanisms retention (1)
- medullary thyroid cancer (1)
- methionine pet (1)
- microenvironment (1)
- microglial cells (1)
- molecular imaging (1)
- nuclear cardiology (1)
- papillary (1)
- phosphorylation (1)
- pooled (1)
- positron-emission-tomography (1)
- power-station accident (1)
- prognostic value (1)
- radiation (1)
- radiotracer (1)
- repair (1)
- response evaluation (1)
- risk (1)
- sepsis (1)
- skin hemagioma (1)
- somatostatin (1)
- stem-cell transplantation (1)
- surgery (1)
- surgical treatment (1)
- therapeutic target (1)
- thyroid cancer (1)
- treatment response (1)
- trial (1)
- whole body MRI (1)
- whole-body (1)
Institute
- Klinik und Poliklinik für Nuklearmedizin (13) (remove)
DNA double strand break (DSB) formation induced by ionizing radiation exposure is indicated by the DSB biomarkers \(\gamma\)-H2AX and 53BP1. Knowledge about DSB foci formation in-vitro after internal irradiation of whole blood samples with radionuclides in solution will help us to gain detailed insights about dose-response relationships in patients after molecular radiotherapy (MRT). Therefore, we studied the induction of radiation-induced co-localizing \(\gamma\)-H2AX and 53BP1 foci as surrogate markers for DSBs in-vitro, and correlated the obtained foci per cell values with the in-vitro absorbed doses to the blood for the two most frequently used radionuclides in MRT (I-131 and Lu-177). This approach led to an in-vitro calibration curve. Overall, 55 blood samples of three healthy volunteers were analyzed. For each experiment several vials containing a mixture of whole blood and radioactive solutions with different concentrations of isotonic NaCl-diluted radionuclides with known activities were prepared. Leukocytes were recovered by density centrifugation after incubation and constant blending for 1 h at 37°C. After ethanol fixation they were subjected to two-color immunofluorescence staining and the average frequencies of the co-localizing \(\gamma\)-H2AX and 53BP1 foci/nucleus were determined using a fluorescence microscope equipped with a red/green double band pass filter. The exact activity was determined in parallel in each blood sample by calibrated germanium detector measurements. The absorbed dose rates to the blood per nuclear disintegrations occurring in 1 ml of blood were calculated for both isotopes by a Monte Carlo simulation. The measured blood doses in our samples ranged from 6 to 95 mGy. A linear relationship was found between the number of DSB-marking foci/nucleus and the absorbed dose to the blood for both radionuclides studied. There were only minor nuclide-specific intra-and inter-subject deviations.
Background
Solitary metastases to the pancreas are rare. Therefore the value of resection in curative intention remains unclear. In the literature there are several promising reports about resection of solitary metastasis to the pancreas mainly of renal origin.
Case presentation
Here we report for the first time on the surgical therapy of a 1.5 cm solitary pancreatic metastasis of an adrenocortical carcinoma. The metastasis occurred almost 6 years after resection of the primary tumor. A partial pancreatoduodenectomy was performed and postoperatively adjuvant mitotane treatment was initiated. During the follow-up of 3 years after surgery no evidence of tumor recurrence occurred.
Conclusion
Resection of pancreatic tumors should be considered, even if the mass is suspicious for metastatic disease including recurrence of adrenocortical cancer.
Multiple myeloma (MM) remains an essentially incurable hematologic malignancy. However, new treatment modalities and novel drugs have been introduced and thus additional tools for therapy monitoring are increasingly needed. Therefore, we evaluated the radiotracers \(^{11}\)C-Methionine (paraprotein-biosynthesis) and \(^{18}\)F-FDG (glucose-utilization) for monitoring response to anti-myeloma-therapy and outcome prediction. Influence of proteasome-inhibition on radiotracer-uptake of different MM cell-lines and patient-derived CD138\(^{+}\) plasma cells was analyzed and related to tumor-biology. Mice xenotransplanted with MM. 1S tumors underwent MET- and FDG-\(\mu\)PET. Tumor-to-background ratios before and after 24 h, 8 and 15 days treatment with bortezomib were correlated to survival. Treatment reduced both MET and FDG uptake; changes in tracer-retention correlated with a switch from high to low CD138-expression. In xenotransplanted mice, MET-uptake significantly decreased by 30-79% as early as 24 h after bortezomib injection. No significant differences were detected thus early with FDG. This finding was confirmed in patient-derived MM cells. Importantly, early reduction of MET-but not FDG-uptake correlated with improved survival and reduced tumor burden in mice. Our results suggest that MET is superior to FDG in very early assessment of response to anti-myeloma-therapy. Early changes in MET-uptake have predictive potential regarding response and survival. MET-PET holds promise to individualize therapies in MM in future.